Abstract
Thalidomide is a hyprotic/sedative drug which was withdrawn from the market because of teratogenicity. However, it has been established to be useful for the treatment of various diseases, including Hansen's disease and various cancers. Thalidomide elicits a wide range of pharmacological effects, including anti-cachexia, antitumor-promoting, antiangiogenic, immunosuppressing, antiviral, hypoglycemic, cell differentiation-inducing and antimetastatic activities. It appears to be a multitarget drug and hypothetical target events/molecules of thalidomide include TNF-α production, nuclear androgen receptor, cyclooxygenases, nuclear retinoic acid receptor, aminopeptidases and α-glucesidase. Specific and potent compounds acting on each of these target phenomena/molecules have been prepared by appropriate modification of the thalidomide structure and are expected to be superior lead compounds for novel immunomodulators, antiangiogenic agents and antitumor-promoting agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
